Hypertrophic cardiomyopathy: Difference between revisions
No edit summary |
|||
| Line 14: | Line 14: | ||
==[[Hypertrophic cardiomyopathy overview|Overview]]== | ==[[Hypertrophic cardiomyopathy overview|Overview]]== | ||
== | ==Historical Perspective== | ||
==[[Hypertrophic cardiomyopathy classification|Classification]]== | ==[[Hypertrophic cardiomyopathy classification|Classification]]== | ||
| Line 22: | Line 22: | ||
==[[Hypertrophic cardiomyopathy causes|Causes]]== | ==[[Hypertrophic cardiomyopathy causes|Causes]]== | ||
==[[Hypertrophic cardiomyopathy epidemiology and demographics|Epidemiology and | ==[[Hypertrophic cardiomyopathy epidemiology and demographics|Epidemiology and Demographics]]== | ||
==Risk Factors== | ==Risk Factors== | ||
==[[Hypertrophic cardiomyopathy screening|Screening]]== | ==[[Hypertrophic cardiomyopathy screening|Screening]]== | ||
| Line 30: | Line 30: | ||
==Diagnosis== | ==Diagnosis== | ||
Diagnostic Study of Choice| [[Hypertrophic cardiomyopathy symptoms|History and Symptoms]] | [[Hypertrophic cardiomyopathy physical examination|Physical examination]] | Laboratory findings | [[Hypertrophic cardiomyopathy electrocardiogram|Electrocardiogram]] | X Ray | Echocardiography and Ultrasound | [[Hypertrophic cardiomyopathy CT|CT]] Scan | [[Hypertrophic cardiomyopathy MRI|MRI]] |Other Imaging Findings | Other Diagnostic Studies. | |||
==Treatment== | ==Treatment== | ||
*'''Medical therapy''', '''Interventions, Surgery, Primary Prevention, Secondary Prevention, Cost Effectiveness of Therapy, Future or Investigational Therapy'''<br /> | |||
*'''Medical therapy | |||
====Contraindicated medications==== | ====Contraindicated medications==== | ||
Revision as of 14:36, 20 January 2020
For patient information click here
| Hypertrophic cardiomyopathy | |
 | |
|---|---|
| Hypertrophic cardiomyopathy. Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology |
|
Hypertrophic Cardiomyopathy Microchapters |
|
Differentiating Hypertrophic Cardiomyopathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hypertrophic cardiomyopathy On the Web |
|
Directions to Hospitals Treating Hypertrophic cardiomyopathy |
|
Risk calculators and risk factors for Hypertrophic cardiomyopathy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: Hypertrophic cardiomyopathy or HCM, Asymmetric septal hypertrophy or ASH, Hypertrophic obstructive cardiomyopathy, HOCM, Idiopathic hypertrophic subaortic stenosis or IHSS, familial isolated hypertrophic obstructive cardiomyopathy, familial isolated hypertrophic subaortic stenosis, familial or idiopathic hypertrophic subaortic stenosis, familial or idiopathic hypertrophic obstructive cardiomyopathy, primitive hypertrophic obstructive cardiomyopathy, primitive hypertrophic subaortic stenosis, muscular subaortic stenosis, apical hypertrophic cardiomyopathy, which is also known as nonobstructive hypertrophic cardiomyopathy and Japanese variant hypertrophic cardiomyopathy or the Yamaguchi variant (since the first cases described were all in individuals of Japanese descent)
Overview
Historical Perspective
Classification
Pathophysiology
Differentiating Hypertrophic Cardiomyopathy from other Diseases
Causes
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice| History and Symptoms | Physical examination | Laboratory findings | Electrocardiogram | X Ray | Echocardiography and Ultrasound | CT Scan | MRI |Other Imaging Findings | Other Diagnostic Studies.
Treatment
- Medical therapy, Interventions, Surgery, Primary Prevention, Secondary Prevention, Cost Effectiveness of Therapy, Future or Investigational Therapy
Contraindicated medications
Idiopathic hypertrophic subaortic stenosis is considered an absolute contraindication to the use of the following medications:
Special Patient Populations
Asymptomatic Patients | Management During Childhood | Hypotension/Cardiovascular collapse | Pregnancy
2011 ACCF/AHA Guideline Recommendations
Diagnostic testing:
Electrocardiogram | Echocardiography | Stress Testing | Cardiac Magnetic Resonance | Cardiac CT | Positron Emission Tomography
Management:
- Asymptomatic patients: Asymptomatic patients
- Symptomatic patints: Pharmacologic Management
| Invasive Therapies | Alcohol septal ablation | Septal Myectomy | Pacing | Selection of Patients for ICDs | Selection of ICD-Device type | Selection of Patients for Heart Transplantation
- Special Clinical Scenarios: Patients With LV Systolic Dysfunction | Sudden cardiac death Risk Stratification | Participation in Competitive or Recreational Sports and Physical Activity | Management of Atrial Fibrillation | Pregnancy/Delivery | Concomitant Coronary Disease